Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

2018-09-08

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Additional Metadata
Persistent URL	doi.org/10.1007/s40273-018-0708-4, hdl.handle.net/1765/111392
Journal	PharmacoEconomics
Organisation	Institute for Medical Technology Assessment (iMTA)
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Büyükkaramikli, N., de Groot, S., Riemsma, R., Fayter, D., Armstrong, N., Portegijs, P., … Al, M. (2018). Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. doi:10.1007/s40273-018-0708-4